Stock Snapshot from
Eli Lilly & CoAdd to My Watchlist
LLY:USNew YorkIndustry: Medical-Drugs
- 54.92Last
- 0.22 -0.40%Today's Change
- 55.14Previous Close
- 52 Week Low - High
Earnings
| EPS: Year Actual ttm | 3.610 |
| EPS: Year Est. 12/13 ttm | 3.919 |
| EPS: Quarterly Actual 3/13 | 1.14 |
| EPS: Quarterly Est. 6/13 | 1.01 |
| Price/Earnings ttm | 15.21 |
| Relative Price/Earnings | 0.942 |
| Earnings Growth Rate | -5.90 |
Company Description
| Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company's products are sold in countries around the world. Eli Lilly's products include neuroscience products, endocrine products, anti-infectives, cardiovascular agents, oncology products, and animal health products. | |
| Revenue | $23 billion |
| Net Income | $4 billion |
| Total Assets | $34 billion |
| Employees | 38,350 |
| Web Site | www.lilly.com |
Latest Headlines
- Novartis Expands Alzheimer’s Pursuit as Rivals’ Drugs Fail
- Teva Bets on Reformulating Drugs as Investors Say ‘Show Me’
- Vitamins That Cost Pennies a Day Seen Delaying Dementia: Health
- Lilly, ThyssenKrupp, Adidas, Nintendo: Intellectual Property
- Lilly, ThyssenKrupp, Adidas, Nintendo: Intellectual Property
- Canada’s Supreme Court Won’t Hear Eli Lilly Appeal on Zyprexa
- Jolie Mastectomy Fuels Debate on Breast Cancer Treatment: Health
- Lilly CEO Lechleiter Has Scheduled Surgery to Repair Heart
- Lilly Stops Development on Lymphoma Drug After Failed Study
- Bristol-Myers, Disney, Google, Steele: Intellectual Property
Watchlist
Unless indicated otherwise: intraday data is at least 15 minutes delayed; mutual fund NAVs are updated at the close of every market day; all prices are in the local currency; Time is ET.